These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8380021)

  • 1. Toxicity of amphotericin B emulsion formulations.
    Washington C; Lance M; Davis SS
    J Antimicrob Chemother; 1993 May; 31(5):806-8. PubMed ID: 8380021
    [No Abstract]   [Full Text] [Related]  

  • 2. Amphotericin B in fat emulsion.
    Kintzel PE
    Am J Health Syst Pharm; 1996 Nov; 53(22):2701. PubMed ID: 8931810
    [No Abstract]   [Full Text] [Related]  

  • 3. Amphotericin B toxicity reduced by administration in fat emulsion.
    Anderson RP; Clark DA
    Ann Pharmacother; 1995 May; 29(5):496-500. PubMed ID: 7655134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute renal failure with amphotericin B in lipid emulsion.
    Gales MA; Gales BJ; Alford KM
    Ann Pharmacother; 1996 Sep; 30(9):1036. PubMed ID: 8876871
    [No Abstract]   [Full Text] [Related]  

  • 5. [Use of amphotericin B in lipid emulsions: does it prevent its toxicity in critically ill patients?].
    Hernández G; Altermatt F; Bernucci F; Acuña D; Apablaza F; Valenzuela F; Lefio A; Pérez C; Bugedo G; Castillo L
    Rev Med Chil; 2000 Oct; 128(10):1101-7. PubMed ID: 11349508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case-control study of amphotericin B in a triglyceride fat emulsion versus conventional amphotericin B in patients with AIDS.
    Manfredi R; Chiodo F
    Pharmacotherapy; 1998; 18(5):1087-92. PubMed ID: 9758320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vivo activity and tolerance of conventional formulation versus fat emulsion formulation of amphotericin B in experimental disseminated candidiasis in neutropenic rabbits.
    Chavanet P; Duong M; Buisson M; Hamel H; Dubois C; Bonnin A; Portier H
    J Antimicrob Chemother; 1997 Mar; 39(3):427-30. PubMed ID: 9096196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azar.
    Thakur CP
    Trans R Soc Trop Med Hyg; 1994; 88(6):698-9. PubMed ID: 7886778
    [No Abstract]   [Full Text] [Related]  

  • 9. Amphotericin B does not mix with fat emulsion.
    Trissel LA
    Am J Health Syst Pharm; 1995 Jul; 52(13):1463-4. PubMed ID: 7671046
    [No Abstract]   [Full Text] [Related]  

  • 10. Amphotericin B--fat emulsion in treatment of visceral leishmaniasis--a cost effective substitute for liposomal amphotericin B.
    Singh GP; Saxena RK; Priyadarshy V
    J Indian Med Assoc; 2010 Jan; 108(1):27-8. PubMed ID: 20839576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients.
    Moreau P; Milpied N; Fayette N; Ramée JF; Harousseau JL
    J Antimicrob Chemother; 1992 Oct; 30(4):535-41. PubMed ID: 1490923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amphotericin B infused in 20% lipid emulsion.
    Ryan KA
    J Intraven Nurs; 1996; 19(3):123-5. PubMed ID: 8788829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of amphotericin B in lipid emulsion.
    O'Neil MG; Lapointe M
    Crit Care Med; 1997 May; 25(5):892-3; author reply 893-4. PubMed ID: 9187614
    [No Abstract]   [Full Text] [Related]  

  • 14. Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia.
    Pascual B; Ayestaran A; Montoro JB; Oliveras J; Estibalez A; Julia A; Lopez A
    Ann Pharmacother; 1995 Dec; 29(12):1197-201. PubMed ID: 8672820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of amphotericin B in lipid emulsion.
    Devlin J; Bailey E; Zarowitz B
    Crit Care Med; 1997 May; 25(5):892; author reply 893-4. PubMed ID: 9187613
    [No Abstract]   [Full Text] [Related]  

  • 16. Precipitation of amphotericin B from i.v. fat emulsion.
    Heide PE
    Am J Health Syst Pharm; 1997 Jun; 54(12):1449. PubMed ID: 9194992
    [No Abstract]   [Full Text] [Related]  

  • 17. Poor immediate tolerability of amphotericin B lipid emulsion in patients with haematological malignancies. Haematology-Microbiology Group.
    Laverdière M; Habel F; Weiss K; Delorme J; Dubois G; Gagnon N; Bélanger R
    J Antimicrob Chemother; 1997 Dec; 40(6):910-2. PubMed ID: 9462450
    [No Abstract]   [Full Text] [Related]  

  • 18. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.
    Chavanet PY; Garry I; Charlier N; Caillot D; Kisterman JP; D'Athis M; Portier H
    BMJ; 1992 Oct; 305(6859):921-5. PubMed ID: 1458072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of amphotericin B in an extemporaneously prepared i.v. fat emulsion.
    Lopez RM; Ayestaran A; Pou L; Montoro JB; Hernandez M; Caragol I
    Am J Health Syst Pharm; 1996 Nov; 53(22):2724-7. PubMed ID: 8931814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.
    Schöffski P; Freund M; Wunder R; Petersen D; Köhne CH; Hecker H; Schubert U; Ganser A
    BMJ; 1998 Aug; 317(7155):379-84. PubMed ID: 9694753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.